Program
omecamtiv mecarbil
Also written as “CK-1827452”, “Omecamtiv mecarbil” and “Omecamtiv Mecarbil (OM)”.
Its studies are mostly in Heart Failure · Ventricular Dysfunction, Left, led by Cytokinetics.
Furthest: phase 3, since Sep 30, 201616 company-led studies, 1 open or runningNext primary completion: Sep 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cytokinetics | 161 open or running | phase 3since Sep 30, 2016 | Dec 21, 2007 | Sep 2027phase 3 · NCT06736574 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Dec 21, 2007.
- May 20, 2008Phase 2 study in Heart FailureNCT00682565 · 94 enrolled · Georgia, Russian Federation
- Jul 15, 2009Phase 2 study in Heart FailureNCT00941681 · 35 enrolled · Georgia
- Feb 25, 2010Phase 2 study in Heart FailureNCT01077167
- Feb 17, 2011Phase 2 study in Heart FailureNCT01300013 · 614 enrolled · United States, Australia, Belgium and more
- Jun 22, 2011Phase 1 study in Heart FailureNCT01380223 · 35 enrolled · United Kingdom
- Oct 16, 2012Phase 1 study in Heart FailureNCT01737866 · 13 enrolled · United States
- Jan 18, 2013Phase 2 study in Ventricular Dysfunction, LeftNCT01786512 · 544 enrolled · United States, Australia, Belgium and more
- Jun 17, 2015Phase 1 study in Heart FailureNCT02601001 · 50 enrolled · Japan
- Feb 25, 2016Phase 2 study in Heart FailureNCT02695420 · 81 enrolled · Japan
- Sep 30, 2016Phase 3 study in Heart FailureNCT02929329 · 8,256 enrolled · United States, Argentina, Australia and more
- Nov 15, 2018Phase 3 study in Heart Failure With Reduced Ejection FractionNCT03759392 · 276 enrolled · United States, Canada, France and more
- Nov 7, 2019Phase 1 study in QT Intervals ChangesNCT04175808 · 70 enrolled · United Kingdom
- Jul 6, 2020Phase 3 study in Chronic Heart Failure With Reduced Ejection FractionNCT04464525
- Dec 3, 2024Phase 3 study in Heart FailureNCT06736574 · 1,800 planned · United States, Canada, China and more
Ahead
- Sep 2027Primary completion: phase 3 study in Heart FailureNCT06736574
TargetBeta
“Cardiac myosin activator”ChEMBL 37, by rule
Other programs on the same 7 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mavacamtenrule | Bristol-Myers Squibb | phase 4 | 21 |
| danicamtivrule | Bristol-Myers Squibb | phase 3 | 7 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06736574Heart Failure · United States, Canada, China and more | 3 | Recruiting | Sep 2027 | 1,800 |
| NCT04464525Chronic Heart Failure With Reduced Ejection Fraction | 3 | Withdrawn | Nov 27, 2026 | 0 |
| NCT04175808QT Intervals Changes · United Kingdom | 1 | Completed | Mar 4, 2020 | 70 |
| NCT03759392Heart Failure With Reduced Ejection Fraction · United States, Canada, France and more | 3 | Completed | Nov 8, 2021 | 276 |
| NCT02929329Heart Failure · United States, Argentina, Australia and more | 3 | Completed | Sep 14, 2020 | 8,256 |
| NCT02695420Heart Failure · Japan | 2 | Completed | Apr 6, 2017 | 81 |
| NCT02601001Heart Failure · Japan | 1 | Completed | Jan 6, 2016 | 50 |
| NCT01786512Ventricular Dysfunction, Left · United States, Australia, Belgium and more | 2 | Completed | Jul 22, 2015 | 544 |
| NCT01737866Heart Failure · United States | 1 | Completed | Jan 2013 | 13 |
| NCT01380223Heart Failure · United Kingdom | 1 | Completed | Apr 2006 | 35 |
| NCT01300013Heart Failure · United States, Australia, Belgium and more | 2 | Completed | Apr 2013 | 614 |
| NCT01077167Heart Failure | 2 | Withdrawn | May 2011 | 0 |
| NCT00941681Heart Failure · Georgia | 2 | Completed | Oct 2009 | 35 |
| NCT00682565Heart Failure · Georgia, Russian Federation | 2 | Completed | Nov 2008 | 94 |
| NCT00748579Heart Failure · United States, Canada | 2 | Terminated | Nov 2008 | 2 |
| NCT00624442Heart Failure · United States, Georgia, Russian Federation and more | 2 | Completed | Feb 2009 | 45 |
How it is read
Names in the registry
- “CK-1827452”, 18 entries
- “omecamtiv mecarbil”, 10 entries
- “Omecamtiv mecarbil”, 4 entries
- “Omecamtiv Mecarbil (OM)”, 2 entries
- “Omecamtiv Mecarbil”, 2 entries
Conditions, from the studies’ own filings
- Heart Failure, 14 studies
- Ventricular Dysfunction, Left, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.